Morpholino

MO2-cyp19a1a

ID
ZDB-MRPHLNO-180918-1
Name
MO2-cyp19a1a
Previous Names
None
Target
Sequence
5' - GGAGCAGATCACCTGCCATAAGAAC - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
Translation-blocking MO.
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO2-cyp19a1a
Expressed Gene Anatomy Figures
tph2 Fig. 4 from Ulhaq et al., 2018
Phenotype
Phenotype resulting from MO2-cyp19a1a
Phenotype of all Fish created by or utilizing MO2-cyp19a1a
Phenotype Fish Conditions Figures
behavior process quality, ameliorated WT + MO2-cyp19a1a chemical treatment by environment: fluoxetine Fig. 5 from Ulhaq et al., 2018
whole organism tph2 expression amount, ameliorated WT + MO2-cyp19a1a chemical treatment by environment: 17beta-estradiol Fig. 4 from Ulhaq et al., 2018
behavior process quality, ameliorated WT + MO2-cyp19a1a chemical treatment by environment: 17beta-estradiol Fig. 5 from Ulhaq et al., 2018
behavior process quality, abnormal WT + MO2-cyp19a1a control Fig. 5 from Ulhaq et al., 2018
heart contraction decreased rate, abnormal WT + MO2-cyp19a1a control Fig. 5 from Ulhaq et al., 2018
heart contraction rate, ameliorated WT + MO2-cyp19a1a chemical treatment by environment: 17beta-estradiol Fig. 5 from Ulhaq et al., 2018
raphe nucleus ab2-serotonin labeling amount, ameliorated WT + MO2-cyp19a1a chemical treatment by environment: 17beta-estradiol Fig. 4 from Ulhaq et al., 2018
raphe nucleus ab2-serotonin labeling decreased distribution, abnormal WT + MO2-cyp19a1a standard conditions Fig. 4 from Ulhaq et al., 2018
diencephalon ab2-serotonin labeling decreased distribution, abnormal WT + MO2-cyp19a1a standard conditions Fig. 4 from Ulhaq et al., 2018
whole organism tph2 expression decreased amount, abnormal WT + MO2-cyp19a1a control Fig. 4 from Ulhaq et al., 2018
heart contraction rate, ameliorated WT + MO2-cyp19a1a chemical treatment by environment: fluoxetine Fig. 5 from Ulhaq et al., 2018
diencephalon ab2-serotonin labeling amount, ameliorated WT + MO2-cyp19a1a chemical treatment by environment: 17beta-estradiol Fig. 4 from Ulhaq et al., 2018
behavior process quality, ameliorated WT + MO2-cyp19a1a chemical treatment by environment: serotonergic agonist Fig. 5 from Ulhaq et al., 2018
heart contraction rate, ameliorated WT + MO2-cyp19a1a chemical treatment by environment: serotonergic agonist Fig. 5 from Ulhaq et al., 2018
Citations